The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Retatrutide vs Wegovy

Retatrutide vs Wegovy (semaglutide 2.4 mg): Phase 3 data shows approximately 24.2% body weight reduction with retatrutide vs 14.9% with semaglutide — a difference of roughly 9 percentage points.

Weight Loss Data

Wegovy (STEP-1): 14.9% at 68 weeks. Retatrutide (TRIUMPH-1): 24.2% at 48 weeks. For a 250 lb subject: Wegovy produces ~37 lbs of weight loss; retatrutide produces ~60 lbs — approximately 23 lbs more.

Mechanism Difference

Wegovy (semaglutide): GLP-1 receptor agonism — appetite suppression, insulin secretion, gastric emptying delay. Retatrutide: adds GIP and glucagon receptor agonism — enhanced insulin sensitivity and increased energy expenditure.

Availability

Wegovy: FDA-approved, available by prescription. Retatrutide: Phase 3 trials ongoing, not yet approved. Research-grade versions of both are available from research chemical suppliers for laboratory use.